Innovative Noninvasive HPV Screening Using a Feminine Pad: A Pilot Study for Enhanced Cervical Cancer Detection
Authors:
- Rodrigo Aldariz-AmayaRARodrigo Aldariz-Amaya
- Miriam Rodríguez-EsquivelMRMiriam Rodríguez-Esquivel
- Alfonso Ruiz-RomeroARAlfonso Ruiz-Romero
- Fernanda AnthorFAFernanda Anthor
- Emmanuel MaresEMEmmanuel Mares
- Marco Antonio Fuentes-GarciaMFMarco Antonio Fuentes-Garcia
- Teresa Apresa-GarcíaTATeresa Apresa-García
- Ricardo López-RomeroRLRicardo López-Romero
- Emmanuel SalcedoESEmmanuel Salcedo
- María de Jesús Nambo-LucioMNMaría de Jesús Nambo-Lucio
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2025 (1) , 9344596
Abstract
Background: Human papillomavirus (HPV) is a major contributor to cervical cancer (CC), with Papanicolaou (Pap) smears and HPV testing serving as primary screening tools in developed countries. The effectiveness of these methods can vary based on a country’s epidemiological and socioeconomic context. This study introduces an innovative, noninvasive method employing surgical gauze worn as a feminine pad for HPV detection, with the aim of simplifying and improving screening processes. Materials and Methods: A total of 184 participants, including individuals classified as healthy, with cervical precursor lesions, or as with confirmed CC, were enrolled. All participants underwent cytological and colposcopic evaluations, with biopsies taken in cases of abnormal results. Each participant wore the device for 8 h, after which DNA was extracted from the soiled devices and analyzed via PCR for mitochondrial and HPV–DNA. Sensitivity and specificity were calculated to assess the effectiveness of HPV detection. Sensitivity and specificity values for HPV detection were obtained. Analysis of diagnostic tests was performed by OpenEpi software. Results: The device was well‐received, with high compliance among participants. PCR analysis revealed that 17.7% of healthy, 72.1% of precursor‐lesion cases, and 97.1% of CC cases tested positive for HPV. The calculated sensitivity and specificity for detecting high‐grade lesions (CIN2+ or CIN2/3 and CC) were 94.81% and 51.28%, respectively. For CC detection, sensitivity was 97.14% with a specificity of 54.39%. Conclusions: The use of this noninvasive device demonstrated a significant correlation with clinical outcomes, supporting its potential as an effective and accessible tool for HPV screening. This method offers a promising alternative to conventional screening techniques, particularly in settings where traditional methods face logistical and socioeconomic challenges.Keywords
Funding Information
- Instituto Mexicano del Seguro Social
This publication has 38 references indexed in Scilit:
- Cervical Cancer ScreeningJAMA, 2023
- Women's critical experiences with the pap smear for the development of cervical cancer screening devicesHeliyon, 2023
- IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: Quality assurance and quality control issuesJournal of Clinical Virology, 2022
- Women’s perception of cervical cancer pap smear screeningNursing Open, 2022
- Feasibility and Accuracy of Menstrual Blood Testing for High-risk Human Papillomavirus Detection With Capture SequencingJAMA Network Open, 2021
- 2020 list of human papillomavirus assays suitable for primary cervical cancer screeningClinical Microbiology and Infection, 2021
- Knowledge of Cervical Cancer and Adherence to Pap Smear Screening Test Among Female University Students in a Multiethnic Institution, USAJournal of the National Medical Association, 2020
- Volatolome of the Female Genitourinary Area: Toward the Metabolome of Cervical CancerArchives of Medical Research, 2018
- HPV prevalence and accuracy of HPV testing to detect high‐grade cervical intraepithelial neoplasiaInternational Journal of Cancer, 2011
- HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in MexicoCancer Causes & Control, 2010